Baxter launches swine flu vaccine

Celvapan is one of two vaccines now available for swine flu prophylaxis in high-risk patients.

Celvapan should be used in accordance with official guidance. The dose recommendations are based on safety and immunogenicity data available from the administration of a vaccine containing 7.5 microgram HA derived from A/Vietnam/1203/2004 (H5N1) in adults, including the elderly. Doses were given on days 0 and 21.

The decision to use Celvapan in each age group should take into account the extent of the clinical data available with the version containing H5N1 antigen and the disease characteristics of the current influenza pandemic.

View Celvapan drug record

Further information: Baxter


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

First oral GLP-1 agonist launched for type II diabetes

First oral GLP-1 agonist launched for type II diabetes

Prescribers can now consider a GLP-1 agonist as an...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Don't prescribe analgesics for chronic pain, new NICE guidance advises

Don't prescribe analgesics for chronic pain, new NICE guidance advises

Draft NICE guidance on chronic pain warns that prescribing...